Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2025-01-01 DOI:10.2174/0113816128347722250109042022
Phool Chandra, Manav Ruhela, Prashant Kumar, Mayur Porwal, Anurag Verma, Himanshu Sharma, Neetu Sachan
{"title":"Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.","authors":"Phool Chandra, Manav Ruhela, Prashant Kumar, Mayur Porwal, Anurag Verma, Himanshu Sharma, Neetu Sachan","doi":"10.2174/0113816128347722250109042022","DOIUrl":null,"url":null,"abstract":"<p><p>Nanotechnology has emerged as a promising avenue for targeted drug delivery to the small intestine, offering precise control over drug release and enhanced therapeutic efficacy. This review discusses recent advancements and challenges in nanotechnology-based approaches for targeted drug delivery to the small intestine. The small intestine presents unique challenges for drug delivery, including enzymatic degradation, low permeability, and rapid transit time. Nanotechnology offers solutions to these challenges by providing carriers capable of protecting drugs from degradation, enhancing their absorption, and facilitating site-specific delivery. Various nanocarrier systems have been explored for targeted drug delivery to the small intestine, including liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles. These carriers can be functionalized with ligands targeting specific receptors or transporters expressed on the intestinal epithelium, enabling efficient uptake and intracellular delivery of drugs. Additionally, nanotechnology enables the controlled release of drugs, allowing for sustained and/or triggered release profiles tailored to the physiological conditions of the small intestine. This precise control over drug release can improve therapeutic outcomes while minimizing systemic side effects. Despite the significant progress in nanotechnology-based drug delivery to the small intestine, several challenges remain. These include achieving sufficient drug loading capacity, ensuring biocompatibility and safety of nanocarriers, and addressing regulatory concerns associated with their clinical translation. In conclusion, nanotechnology holds immense potential for targeted drug delivery to the small intestine, offering solutions to overcome the limitations of conventional drug delivery systems. Addressing the remaining challenges will be crucial for realizing the full therapeutic benefits of nanotechnology in treating diseases affecting the small intestine.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":"1939-1957"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128347722250109042022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Nanotechnology has emerged as a promising avenue for targeted drug delivery to the small intestine, offering precise control over drug release and enhanced therapeutic efficacy. This review discusses recent advancements and challenges in nanotechnology-based approaches for targeted drug delivery to the small intestine. The small intestine presents unique challenges for drug delivery, including enzymatic degradation, low permeability, and rapid transit time. Nanotechnology offers solutions to these challenges by providing carriers capable of protecting drugs from degradation, enhancing their absorption, and facilitating site-specific delivery. Various nanocarrier systems have been explored for targeted drug delivery to the small intestine, including liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles. These carriers can be functionalized with ligands targeting specific receptors or transporters expressed on the intestinal epithelium, enabling efficient uptake and intracellular delivery of drugs. Additionally, nanotechnology enables the controlled release of drugs, allowing for sustained and/or triggered release profiles tailored to the physiological conditions of the small intestine. This precise control over drug release can improve therapeutic outcomes while minimizing systemic side effects. Despite the significant progress in nanotechnology-based drug delivery to the small intestine, several challenges remain. These include achieving sufficient drug loading capacity, ensuring biocompatibility and safety of nanocarriers, and addressing regulatory concerns associated with their clinical translation. In conclusion, nanotechnology holds immense potential for targeted drug delivery to the small intestine, offering solutions to overcome the limitations of conventional drug delivery systems. Addressing the remaining challenges will be crucial for realizing the full therapeutic benefits of nanotechnology in treating diseases affecting the small intestine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于纳米技术的小肠靶向药物递送方法:进展与挑战。
纳米技术已经成为小肠靶向药物递送的一种很有前途的途径,可以精确控制药物释放并提高治疗效果。本文综述了基于纳米技术的小肠靶向药物递送方法的最新进展和挑战。小肠对药物递送具有独特的挑战,包括酶降解、低通透性和快速转运时间。纳米技术为这些挑战提供了解决方案,它提供了能够保护药物免受降解、增强其吸收和促进特定位点递送的载体。各种纳米载体系统已经被探索用于靶向药物递送到小肠,包括脂质体,聚合物纳米颗粒,树状大分子和固体脂质纳米颗粒。这些载体可以与靶向肠上皮上表达的特定受体或转运体的配体功能化,从而实现药物的有效摄取和细胞内递送。此外,纳米技术能够控制药物的释放,允许根据小肠的生理条件进行持续和/或触发释放。这种对药物释放的精确控制可以改善治疗效果,同时最大限度地减少全身副作用。尽管在以纳米技术为基础的小肠药物输送方面取得了重大进展,但仍存在一些挑战。这些包括实现足够的药物装载能力,确保纳米载体的生物相容性和安全性,以及解决与临床转化相关的监管问题。总之,纳米技术在小肠靶向药物递送方面具有巨大的潜力,为克服传统药物递送系统的局限性提供了解决方案。解决剩下的挑战对于实现纳米技术在治疗影响小肠的疾病方面的全部治疗效益至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
Type 2 Diabetes and Vascular Complications: Current Perspectives on Pathophysiology and Management Strategies. Therapeutic Potential of Stem Cells in the Treatment and Management of Immunomodulatory Disorders. Reshaping the Future of MASLD - From Pathophysiological Mechanisms to New Therapeutic Horizons. Exosomes in Osteoarthritis: Emerging Roles in Pathogenesis, Diagnosis, and Therapeutic Potential. Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1